Medigene AG announced the appointment of eight leading experts to its new immune oncology focused Scientific Advisory Board (SAB). The SAB will consult the company with regard to strategic options and future perspectives within its research and development activities. The SAB will thereby further strengthen the company's leadership position in the development of innovative cancer immunotherapies. The inaugural members of its new Scientific Advisory Board are: The Chairman, Prof. Dr. Ernst-Ludwig Winnacker, (Co-founder of the company, Professor emeritus at the University of Munich, Department of Biochemistry, former President of the German Research Foundation, former Secretary-General of the European Research Council (ERC), Brussels, former Secretary General of the Human Frontier Science Program in Strasbourg) and the following members: Dr. Micha Drukker: Leader of the research group 'Human Pluripotent Stem Cell Lineage Choice' and head of the core facility 'Human Induced Pluripotent Stem Cells' at the Helmholtz Zentrum Munchen, German Research Center for Environmental Health (GmbH), Munich/Neuherberg, Germany; Prof. Dr. med. Irmela Jeremias: Group Leader at the Research Unit Gene Vectors, Haematologikum, Helmholtz Zentrum Munchen, German Research Center for Environmental Health (GmbH), Munich, Germany; Prof. Dr. Peter H. Krammer: Head of the Division of Immunogenetics in the Tumor Immunology Program at the German Cancer Research Center (DKFZ) and member of the Board of Directors of the National Center for Tumor Diseases (NCT) in Heidelberg, Germany; Dr. Manfred Rudiger: Former CEO of Kiadis Pharma, international experienced life science industry expert, held various executive positions in different companies during last two decades; Dr. Lawrence E. Samelson: Senior Investigator, CCR Deputy Director, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Prof. Dr. Freda Stevenson: Professor of Immunology within Medicine at the University of Southampton, UK.